XML 19 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Assets [Abstract]    
Land $ 15,983,323 $ 21,660,644
Buildings and improvements 102,862,977 133,829,416
Tenant improvements 16,488,066 17,820,948
Lease intangibles 3,776,654 4,110,139
Real estate assets and lease intangibles held for investment, cost 139,111,020 177,421,147
Accumulated depreciation and amortization (33,700,262) (38,725,356)
Real estate assets and lease intangibles held for investment, net 105,410,758 138,695,791
Real estate assets held for sale, net 22,185,742 5,459,993
Real estate assets, net 127,596,500 144,155,784
Other assets:    
Cash, cash equivalents and restricted cash 8,036,496 6,510,428
Deferred leasing costs, net 1,666,135 1,657,055
Goodwill 1,389,000 1,574,000
Investment in Conduit Pharmaceuticals marketable securities (see Notes 2 & 9) 206,177 18,318,521
Deferred tax asset 298,645 346,762
Other Assets, Miscellaneous 3,376,697 3,400,088
Total other assets 14,973,150 31,806,854
TOTAL ASSETS (1) 142,569,650 175,962,638
Liabilities:    
Mortgage notes payable, net 80,977,448 103,685,444
Mortgage notes payable related to properties held for sale, net 21,116,646 4,027,829
Mortgage notes payable, total net 102,094,094 107,713,273
Accounts payable and accrued liabilities 3,290,170 4,770,845
Accrued real estate taxes 1,972,477 1,953,087
Dividends payable 194,784 174,011
Lease liability, net 64,345 16,086
Below-market leases, net 8,625 13,266
Total liabilities 107,624,495 114,640,568
Commitments and contingencies (see Note 10)
Equity:    
Additional paid-in capital 185,770,842 182,331,408
Dividends and accumulated losses (159,374,010) (131,508,785)
Total stockholders' equity before noncontrolling interest 26,535,146 50,954,183
Noncontrolling interest 8,410,009 10,367,887
Total equity 34,945,155 61,322,070
TOTAL LIABILITIES AND EQUITY 142,569,650 175,962,638
Series D Preferred Stock [Member]    
Liabilities:    
Dividends payable 194,784 174,011
Equity:    
Series D Preferred Stock, $0.01 par value per share; 1,000,000 shares authorized; 997,085 shares issued and outstanding (liquidation preference $25.00 per share) as of December 31, 2024 and 890,946 shares issued and outstanding as of December 31, 2023 9,971 8,909
Common Class A [Member]    
Equity:    
Series A Common Stock, $0.01 par value per share, shares authorized: 100,000,000; 12,834,317 shares and 12,265,061 shares were issued and outstanding at December 31, 2024 and December 31, 2023, respectively $ 128,343 $ 122,651